Document:

Exhibit 10.6

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (the “Agreement”) is made as of [●], 2016 by and among iFresh Inc., a
Delaware corporation (including any successor in interest of iFresh Inc. or other entity that issues Registrable Securities (as
defined herein), the “Company”), and the persons listed on Schedule A attached hereto (each an
“Investor,” and collectively, the “Investors”).

 

RECITALS

 

WHEREAS,
the Company’s predecessor was incorporated for the purpose of acquiring, through a stock exchange, asset acquisition or
other similar business combination, an operating business;

 

WHEREAS,
the Company has agreed to acquire NYM Holding, Inc. pursuant to the Merger Agreement dated July 25, 2016 (the “Merger
Agreement”) and certain additional agreements (the “Acquisition”);

 

WHEREAS,
pursuant to the Merger Agreement, the Company will be issuing shares of the Company’s common stock (the “Common
Stock”) to certain persons; and

 

WHEREAS,
in connection with the Acquisition and the Merger Agreement, the Company wishes to grant the Investors certain Piggyback Registration
Rights for the Registrable Securities (as defined below).

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants and agreements set forth herein, the Company and the Investors
hereby agree as follows:

 

AGREEMENT

 

1.           Registration Rights.

 

1.1         Definitions. For purposes of this Section 1:

 

(a)         Holder. For purposes of this Section 1 and Section 2 hereof, the term “Holder” or “Holders”
means any person or persons owning of record Registrable Securities and any affiliate or any permitted transferee or assignee
of record of such Registrable Securities; provided, however, that for purposes of this Agreement, a record holder
of any securities convertible or exercisable into such Registrable Securities shall be deemed to be the Holder of such Registrable
Securities.

 

(b)        Registration. The terms “register,” “registered,” and “registration”
refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the
declaration or ordering of effectiveness of such registration statement.

 

     

     

    

 

(c)         Registrable
Securities. The term “Registrable Securities” means: (i) any and all Common Stock (including
Common Stock underlying securities exercisable for or convertible into Common Stock) beneficially owned by the signatories hereto
on the date hereof as specified on Schedule A hereto (collectively, the “Securities”), (ii) any securities
issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend
or other distribution with respect to, in exchange for or in replacement of, the Securities, provided, that any of the foregoing
securities shall cease to be Registrable Securities upon the earliest to occur of the following: (A) a sale pursuant to an effective
Registration Statement; (B) a sale pursuant to Rule 144 or
any similar provision then in force under the Securities Act (in which case, only such security sold shall cease to be a Registrable
Security); (C) eligibility for sale without current public information requirements and volume or manner of sale restrictions;
or (D) when such securities shall cease to be outstanding.

 

(d)         Registration Statement. The term “Registration Statement” shall mean any registration statement of the
Company filed under the Securities Act that covers the resale of any of the Registrable Securities pursuant to the provisions
of this Agreement, amendments and supplements to such Registration Statement, including post-effective amendments, all exhibits
and all material incorporated by reference in such Registration Statement.

 

(e)         Securities Act. The term “Securities Act” means the Securities Act of 1933, as amended.

 

(f)          SEC. The term “SEC” means the United States Securities and Exchange Commission.

 

1.2         Piggyback Registrations. The Company shall notify all Holders of Registrable Securities in writing at least fifteen
(15) calendar days prior to filing any registration statement under the Securities Act for purposes of effecting an offering
of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities
of the Company, but excluding registration statements relating to (i) any employee benefit plan or (ii) a corporate
reorganization, merger or acquisition) and will afford each such Holder an opportunity to include in such registration statement
all or any part of the Registrable Securities then held by such Holder. Each Holder desiring to include in any such registration
statement all or any part of the Registrable Securities held by such Holder shall, within seven (7) calendar days after receipt
of the above-described notice from the Company, so notify the Company in writing, and in such notice shall inform the Company
of the number of Registrable Securities such Holder wishes to include in such registration statement. If a Holder decides not
to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall
nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration
statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth
herein.

 

    	 	2	 

     

    

 

(a)         Underwriting. If a registration statement under which the Company gives notice under this Section 1 is for an underwritten
offering, then the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder’s
Registrable Securities to be included in a registration pursuant to this Section 1.2 shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the
extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter
into an underwriting agreement in customary form with the managing underwriter or underwriter(s) selected by the Company for such
underwriting. Notwithstanding any other provision of this Agreement, if the managing underwriter(s) determine(s) in good faith
that marketing factors require a limitation of the number of shares to be underwritten, then the managing underwriter(s) may exclude
shares (including Registrable Securities) from the registration and the underwriting, and the number of shares that may be included
in the registration and the underwriting shall be allocated, first, to any person that exercised demand registration rights
in connection with such registration, second, the Company, and third, to all holders of Company securities having
piggyback registration rights (including Holders of Registrable Securities) requesting inclusion of their securities in such registration
statement on a pro rata basis based on the total number of securities for which registration was requested. If any Holder disapproves
of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter,
delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities
excluded or withdrawn from such underwritten offering shall be excluded and withdrawn from such registration.

 

(b)         Company Termination of Registration. The Company reserves the right to terminate any registration under this Section 1.2
at any time and for any reason without liability to any Holder.

 

1.3         Expenses. All expenses incurred in connection with each registration, including without limitation, all registration and
qualification fees, printers’ and accounting fees, and fees and disbursements of counsel for the Company, costs associated
with clearing the Registrable Securities for sale under applicable state securities laws, listing fees, and the Holders’
reasonable expenses in connection with the registration, (but excluding underwriters’ discounts and commissions and fees
and expenses for counsel to the Holders), shall be borne by the Company.

 

1.4         Obligations of the Company. Whenever required to effect the registration of any Registrable Securities under this Agreement,
the Company shall, as expeditiously as reasonably possible:

 

(a)         provide copies to and permit counsel designated by the Holders to review each Registration Statement and all amendments and supplements
thereto no fewer than five (5) calendar days prior to their filing with the SEC;

 

(b)         furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements
of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of the Registrable
Securities owned by them that are included in such registration;

 

(c)         use its best efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other
securities laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be
required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of
process in any such jurisdictions;

 

    	 	3	 

     

    

 

(d)         in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the managing underwriter(s) of such offering (it being understood and agreed that, as a condition to
the Company’s obligations under this clause (d), each Holder participating in such underwriting public offering shall
also enter into and perform its obligations under such an agreement);

 

(e)         as soon as reasonably practicable (but within at least one business day) notify each Holder of Registrable Securities covered
by such Registration Statement at any time when a prospectus relating thereto is required to be delivered under the Securities
Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances then existing, and the Company shall as soon as reasonably
practicable prepare and file with the SEC an amendment or supplement such prospectus in order to cause such prospectus not to
include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances then existing; and

 

(f)          use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on each
securities exchange, interdealer quotation system or other market on which similar securities issued by the Company are then listed.

 

1.5         Furnish Information. the Company may require each selling Holder to furnish to the Company information regarding such Holder
and the distribution of such Registrable Securities as is required by law or the SEC to be disclosed in such Registration Statement,
prospectus, or any amendment or supplement thereto, and the Company may exclude from such registration the Registrable Securities
of any such Holder who unreasonably fails to furnish such information within a reasonable time after receiving such request.

 

1.6         Indemnification. In the event any Registrable Securities are included in a registration statement under Section 1.2 hereof:

 

(a)         By
the Company. the Company will indemnify and hold harmless each Holder and its partners, officers and directors, employees
and agents, successors and assigns and each other person, if any, who controls such Holder within the meaning of the Securities
Act of, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), against any losses, claims, damages, or liabilities (joint or several) (the “Losses”) to which
they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims,
damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions
or violations (collectively a “Violation”):

 

(i)         any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or supplements thereto;

 

    	 	4	 

     

    

 

(ii)         the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements
therein not misleading; or

 

(iii)        any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any federal or state securities law
or any rule or regulation promulgated under the Securities Act, the Exchange Act or any federal or state securities law in connection
with the offering covered by such registration statement;

 

and
the Company will reimburse each such Holder, partner, officer or director, underwriter or controlling person for any legal or
other expenses reasonably incurred by them in connection with defending any such loss, claim, damage, liability or action; provided,
however, that the indemnity agreement contained in this subsection 1.6(a) shall not apply to amounts paid in settlement
of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which
consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage,
liability or action to the extent that (1) it arises out of or is based upon a Violation which occurs in reliance upon and in
conformity with written information furnished expressly for use in connection with such registration by such Holder, partner,
officer, director, underwriter or controlling person of such Holder specifically for inclusion in such Registration Statement
or prospectus or amendment or supplement thereto or (2) in the case of the occurrence of an event of the type specified in Section
1.4(e), the use by such Holder of an outdated or defective prospectus in such Registration Statement after the Company has notified
such Holder in writing that such prospectus is outdated or defective and prior to the receipt by such Holder of such notification
or an amended or supplemented prospectus, but only if and to the extent that following the receipt of the notification or amended
or supplemented prospectus, the misstatement or omission giving rise to such Losses would have been corrected. The Company shall
promptly notify the Holders of the threat or assertion of any proceeding of which the Company is aware in connection with the
transactions contemplated by this Agreement.

 

(b)        By
Selling Holders. Each selling Holder, severally but not jointly, will indemnify and hold harmless the Company, each of its
directors, each of its officers who have signed the registration statement, each person, if any, who controls the Company within
the meaning of the Securities Act, any underwriter against any losses, claims, damages or liabilities (joint or several) to which
the Company or any such director, officer, controlling person, underwriter may become subject under the Securities Act, the Exchange
Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise
out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance
upon and in conformity with written information furnished by such Holder under an instrument duly executed by such Holder specifically
for inclusion in such Registration Statement or prospectus or amendment or supplement thereto; and each such Holder will reimburse
any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling person, underwriter
or other Holder, partner, officer, director or controlling person of such other Holder in connection with defending any such loss,
claim, damage, liability or action; provided, however, that the indemnity agreement contained in this subsection
1.6(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is
effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further,
that the total amounts payable in indemnity by a Holder under this subsection 1.6(b) in respect of any Violation shall not exceed
the net proceeds received by such Holder upon the sale of the Registrable Securities included in the Registration Statement of
which such Violation arises.

 

    	 	5	 

     

    

 

(c)         Notice.
Promptly after receipt by an indemnified party under this Section 1.6 of notice of the commencement of any action (including
any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Section 1.6, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying
party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying
party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however,
that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying
party, if: (1) the indemnifying party has agreed in writing to pay such fees and expenses; and (2) the indemnifying party shall
have failed to promptly assume the defense of such proceeding and to employ counsel reasonably satisfactory to such indemnified
party in any proceeding; or (3) representation of such indemnified party by the counsel retained by the indemnifying party would
be inappropriate due to actual or potential conflict of interests between such indemnified party and any other party represented
by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of
the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party
of any liability to the indemnified party under this Section 1.6.

 

(d)         Contribution.
If the indemnification provided for in this Section 1.6 is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying
such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable by
such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the
relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s)
that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault
of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information
supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission; provided, that in no event shall any contribution by
a Holder hereunder exceed the net proceeds received by such Holder upon the sale of the Registrable Securities included in the
Registration Statement of which such Violation arises.

 

(e)         Survival.
The obligations of the Company and Holders under this Section 1.6 shall survive the completion of any offering of Registrable
Securities in a registration statement, and otherwise.

 

    	 	6	 

     

    

 

1.7         Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the SEC which
may at any time permit the sale of the Registrable Securities to the public without registration, after such time as a public
market exists for the Common Stock, the Company agrees to use commercially reasonable efforts to:

 

(a)         make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act,
at all times after the effective date of the first registration under the Securities Act filed by the Company for an offering
of its securities to the general public; and

 

(b)         file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting requirements).

 

2.           General Provisions.

 

2.1         Notices. Any notice, request or other communication required or permitted hereunder shall be in writing and shall be deemed
to have been duly given if personally delivered, deposited in the international air mail postage prepaid, or sent by facsimile
or e-mail when receipt is electronically confirmed

 

(i) if
to an Investor, as set forth below Investor’s name on the signature page of this Agreement; and

 

(ii) if
to the Company, to the address set forth below:

 

[address]

Attention:

Fax:

 

Any
party hereto (and such party’s permitted assigns) may by notice so given change its address for future notices hereunder.
Notice shall be deemed conclusively given when personally delivered or sent in the manner set forth above.

 

2.2         Amendments and Waivers. This Agreement may be amended only by a writing signed by the Company and each of the Investors
beneficially owning Registrable Securities.

 

2.3         Entire Agreement. This Agreement, together with all the exhibits hereto, constitutes and contains the entire agreement
and understanding of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence,
agreements, understandings, duties or obligations between the parties respecting the subject matter hereof.

 

2.4         Governing
Law. This Agreement shall be governed by and construed exclusively in accordance with the internal laws of the State of New
York, excluding that body of law relating to conflict of laws and choice of law that would result in the application of the substantive
law of another jurisdiction.

 

    	 	7	 

     

    

 

2.5         Jurisdiction; Service; Waivers. ANY ACTION OR PROCEEDING IN CONNECTION WITH
THIS AGREEMENT MAY BE BROUGHT IN A COURT OF RECORD OF THE STATE OF NEW YORK IN THE COUNTY OF NEW YORK. THE PARTIES TO THIS AGREEMENT
HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS OF THE STATE OF NEW YORK, AND SERVICE OF PROCESS MAY BE MADE UPON
THE PARTIES TO THIS AGREEMENT BY MAILING A COPY OF THE SUMMONS AND ANY COMPLAINT TO SUCH PERSON, BY REGISTERED OR CERTIFIED MAIL,
RETURN RECEIPT REQUESTED, AT ITS ADDRESS TO BE USED FOR THE GIVING OF NOTICES UNDER THIS AGREEMENT. BY ACCEPTANCE HEREOF, THE
PARTIES HERETO EACH HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY OBJECTION, INCLUDING, WITHOUT LIMITATION, ANY OBJECTION
TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OF FORUM NON CONVENIENS, WHICH IT MAY NOW OR HEREAFTER HAVE TO THE BRINGING
OR MAINTAINING OF ANY SUCH ACTION OR PROCEEDING IN SUCH JURISDICTION.

 

2.6         Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, then such
provision(s) shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision(s)
were so excluded and shall be enforceable in accordance with its terms.

 

2.7         Third Parties. Nothing in this Agreement, express or implied, is intended to confer upon any person, other than the parties
hereto and their successors and assigns, any rights or remedies under or by reason of this Agreement.

 

2.8         Successors and Assigns. The provisions of this Agreement shall inure to the benefit of, and shall be binding upon, the
successors and permitted assigns of the parties hereto.

 

2.9         Captions. The captions to sections of this Agreement have been inserted for identification and reference purposes only
and shall not be used to construe or interpret this Agreement.

 

2.10       Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

 

2.11       Costs and Attorneys’ Fees. In the event that any action, suit or other proceeding is instituted concerning or arising
out of this Agreement or any transaction contemplated hereunder, the prevailing party shall recover all of such party’s
costs and reasonable attorneys’ fees incurred in each such action, suit or other proceeding, including any and all appeals
or petitions therefrom.

 

2.12       Adjustments for Stock Splits and Certain Other Changes. Wherever in this Agreement there is a reference to a specific number
of Common Stock of the Company, then, upon the occurrence of any subdivision, combination or stock dividend of such class or series of
stock, the specific number of shares so referenced in this Agreement shall automatically be proportionally adjusted to reflect
the effect on the outstanding shares of such class or series of stock by such subdivision, combination or stock dividend.

 

2.13       Aggregation of Stock.
All shares deemed to be “beneficially owned” (as such term is defined under Rule 13d-3 of the Securities Exchange
Act of 1934, as amended) by any entity or person, shall be aggregated together for the purpose of determining the availability
of any rights under this Agreement.

 

    	 	8	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement as of the date and year first above written.

 

	 	iFRESH INC.
	 	 	 
	 	By:	        
	 	Name:	 
	 	Title:	 

 

    	 	9	 

     

    

 

OMNIBUS
INVESTOR SIGNATURE PAGE TO

iFRESH
INC.

REGISTRATION
RIGHTS AGREEMENT

 

	 	 	 
	[Print Name of Investor]	 	[Name of Co-Investor, if applicable]
	 	 	 
	 	 	 
	[Signature]	 	[Signature]
	 	 	 
	Name:                                                                              	 	Name:                                                                              
	 	 	 
	Title:                                                                                	 	Title:                                                                                
	 	 	 
	Mailing Address:	 	Telephone No.:                                                              
	 	 	 
	 	 	Facsimile No:                                                                 
	 	 	 
	 	 	Email Address:                                                              
	 	 	 
	 	 	Taxpayer ID Number:                                                   
	(City, State and Zip)	 	 

 

Counterpart
Signature Page to Registration Rights Agreement 

 

    	 	10	 

     

    

 

SCHEDULE
A

 

Investor
List

 

	Name of Investor	 	Common Stock	 	Common Stock Underlying Exercisable or Convertible Securities
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

 

11Exhibit

Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Double asterisks denote omissions.

Exhibit 10.1

AMENDMENT #1 to License Agreement
This Amendment #1 to License Agreement (the “First Amendment”) is entered into and made effective as of June 9, 2016 (the “First Amendment Effective Date”) and amends that certain License Agreement dated December 6, 2014 (the “License Agreement”), by and between Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and Spark Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 3737 Market Street, Suite 1300, Philadelphia, Pennsylvania 19104 (“Spark”). Pfizer and Spark are referred to herein individually as a “Party” and collectively as the “Parties”.
WHEREAS, the Parties wish to amend the License Agreement to enable the Manufacturing process technology transfer envisioned in Section 4.5.3 of the License Agreement and to supplement the terms of the License Agreement with respect to such technology transfer as set forth herein;
NOW THEREFORE, in consideration of the premises and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each Party, the Parties hereby agree as follows.
		
	1.
	Terms. Capitalized terms used in this First Amendment and not defined herein shall have the respective meanings given to such terms in the License Agreement.

1.1“[**]” means a [**].  
1.2“First Amendment” is defined in the preamble above.
1.3“First Amendment Effective Date” is the first date written above.
1.4“Joint Manufacturing Process Improvement Know-How” means any Know-How that comprises a Joint Manufacturing Process Improvement.
1.5“Joint Manufacturing Process Improvement Patent Right” means any Patent Right, in any form and whether pending or issued, that claims or discloses any Joint Manufacturing Process Improvement.
1.6“Joint Manufacturing Process Improvement Technology” means Joint Manufacturing Process Improvement Know-How and Joint Manufacturing Process Improvement Patent Rights.
1.7“Manufacturing Process Improvements” means any improvements or changes to the Manufacturing Process Technology made by or on behalf of either Party or both of the Parties jointly (when such Improvement is developed by Pfizer, a “Pfizer Manufacturing Process Improvement”; when such Improvement is developed by Spark, a “Spark Manufacturing Process Improvement”; when such Improvement is developed jointly, a “Joint Manufacturing Process Improvement”).  
1.8“Manufacturing Process Technology” means  (a) [**], and such other materials that Spark transfers to Pfizer pursuant to Appendix B to Manufacture SPK-9001 (and for clarity, not materials that may be described in Appendix B, but that Pfizer, its Affiliates or Third Party collaborators of Pfizer owns, Controls or is in possession of, that was not transferred from Spark), and (b) with respect to Spark Know-How (other than materials), [**] as transferred to Pfizer pursuant to Appendix B.
1.9“Manufacturing Technology Transfer Plan” is defined in Section 3.1(a).
1.10“Pfizer Background Manufacturing Know-How” means any Know-How, other than Pfizer Manufacturing Process Improvement Know-How or Joint Manufacturing Process Improvement Know-How, that (a) is Controlled by Pfizer or any of its Affiliates as of the Effective Date or that comes into the Control of Pfizer or any of its Affiliates during the Term (other than through the grant of a license by Spark) and (b) is used by or on behalf of Pfizer in the Manufacture of any Compound or Licensed Product or is disclosed by or on behalf of Pfizer to Spark in connection with the Manufacture of any Compound or Licensed Product.

1.11“Pfizer Background Manufacturing Patent Right” means any Patent Right, other than a Pfizer Manufacturing Process Improvement Patent Right or a Joint Manufacturing Process Improvement Patent Right, in any form and whether pending or issued, that (a) is Controlled by Pfizer or any of its Affiliates as of the Effective Date or comes into the Control of Pfizer or any of its Affiliates during the term of the Agreement (other than through the grant of a license by Spark) and (b) claims or discloses any method of Manufacture of any Compound or Licensed Product.
1.12“Pfizer Background Manufacturing Technology” means Pfizer Background Manufacturing Know-How and Pfizer Background Manufacturing Patent Rights.
1.13“Pfizer Manufacturing Process Improvement Know-How” means any Know-How that comprises a Pfizer Manufacturing Process Improvement that comes into the Control of Pfizer or any of its Affiliates during the Term (other than through the grant of a license by Spark).
1.14“Pfizer Manufacturing Process Improvement Patent Right” means any Patent Right, in any form and whether pending or issued, that (a) comes into the Control of Pfizer or any of its Affiliates during the term of the Agreement (other than through the grant of a license by Spark) and (b) claims or discloses any Pfizer Manufacturing Process Improvement.
1.15“Pfizer Manufacturing Process Improvement Technology” means Pfizer Manufacturing Process Improvement Know-How and Pfizer Manufacturing Process Improvement Patent Rights. 
1.16 “Spark Manufacturing Process Improvement Know-How” means any Know-How that (a) comprises a Spark Manufacturing Process Improvement that comes into the Control of Spark or any of its Affiliates during the Term, and (b) is used by or on behalf of Spark in the Manufacture of any Compound or Licensed Product or is disclosed by or on behalf of Spark to Pfizer in connection with the Manufacture of any Compound or Licensed Product.
1.17“Spark Manufacturing Process Improvement Patent Right” means any Patent Right, in any form and whether pending or issued, that (a) comes into the Control of Spark or any of its Affiliates during the term of the Agreement, (b) is used by or on behalf of Spark in the Manufacture of any Compound or Licensed Product and (c) claims or discloses any Spark Manufacturing Process Improvement.
1.18“Spark Manufacturing Process Improvement Technology” means Spark Manufacturing Process Improvement Know-How and Spark Manufacturing Process Improvement Patent Rights.

		
	2.
	Effects of First Amendment.  This First Amendment amends the License Agreement solely to the extent expressly provided below as of the First Amendment Effective Date.  As so amended, the License Agreement continues in full force and effect and is ratified in all respects. Any references in the License Agreement to the “Agreement” will be deemed to mean the License Agreement as amended by this First Amendment.    

		
	3.
	Amendments.  

3.1Amendment to Section 4.5.3.  The final sentence of Section 4.5.3 is hereby deleted and replaced with “The Parties shall each use Commercially Reasonable Efforts to discharge the responsibilities set forth in Appendix A to the First Amendment (the “Manufacturing Technology Transfer Plan”):
(a) Transfer of Manufacturing Process Technology to Pfizer.  Spark shall transfer or cause to be transferred to Pfizer the Manufacturing Process Technology in order for Pfizer and Spark to perform its respective activities set forth in the Manufacturing Technology Transfer Plan.  
(b) Expenses.  Each Party shall bear its own expenses in carrying out its responsibilities under the Manufacturing Technology Transfer Plan, provided that Spark’s obligation to carry out its responsibilities under the Manufacturing Technology Transfer Plan shall be subject to the following: (a) for Spark personnel time in excess of an aggregate of [**] person-days, Pfizer shall pay Spark for such additional resources  required for Spark to carry out its responsibilities under the Manufacturing Technology Transfer Plan, and (b) reasonable limitations on the availability of applicable Spark personnel.”

3.2Manufacturing Process Improvements.  The following new Section 5.8 is hereby inserted into the License Agreement immediately following Section 5.7 thereof:
“5.8  Manufacturing Process Intellectual Property.
5.8.1    Ownership.  The Parties shall own Manufacturing Process Improvements in accordance with Section 5.2 (disregarding the proviso in Section 5.2.3).
5.8.2    Licenses.  Without limiting the licenses granted in Section 2:
		
	(a) 
	Subject to the terms of this Agreement and, as applicable, the terms of the Existing Spark License Agreements, Spark hereby grants to Pfizer a worldwide license, (i) [**], with the right to sublicense to Pfizer Affiliates (and without any right to sublicense to any Third Party, whether for the [**] or Licensed Products) and (ii) as to Manufacturing processes other than [**], with the right to sublicense to Pfizer Affiliates and to Third Parties, in the case of (i) and (ii) under Manufacturing Process Technology and Spark Manufacturing Process Improvement Technology and under Spark’s interest in Joint Manufacturing Process Improvement Technology, to Manufacture Compounds and Licensed Products, which license shall be subject to the terms of this Agreement applicable to Compounds and Licensed Products, and shall be an exclusive license subject to Spark’s retained right to Manufacture Compounds and Licensed Products in order to perform its obligations under Phase I/II Clinical Trials and the Manufacturing Technology Transfer Plan.

		
	(b) 
	Subject to the terms of this Agreement (and for the avoidance of doubt without limiting Pfizer’s exclusivity obligations under Section 2.10) and, as applicable, the terms of the Existing Spark License Agreements, Spark hereby grants to Pfizer a fully paid-up, royalty-free, non-exclusive, irrevocable, perpetual, worldwide license, (i) as to any [**], with the right to sublicense to Pfizer Affiliates (and without any right to sublicense to any Third Party, whether for the [**] or products) and (ii) as to Manufacturing processes [**], with the right to sublicense to Pfizer Affiliates and to Third Parties , in the case of (i) and (ii) under Manufacturing Process Technology and Spark Manufacturing Process Improvement Technology and under Spark’s interest in Joint Manufacturing Process Improvement Technology to Manufacture compounds and products other than the Compounds and the Licensed Products, which license shall be royalty-free; provided, however, the license granted under this Section 5.8.2(b) shall exclude the right to use the Manufacturing Process Technology, Spark Manufacturing Process Improvement Technology or Joint Manufacturing Process Improvement Technology for the Manufacture of compounds or [**]).

		
	(c) 
	Spark hereby grants to Pfizer a fully paid-up, royalty-free, semi-exclusive, irrevocable, perpetual, worldwide license, with the right to sublicense under Spark’s interest in any of its improvements or changes to Pfizer Background Manufacturing Technology to Manufacture compounds and products.

		
	(d) 
	Subject to the terms of this Agreement, Pfizer hereby grants to Spark a fully paid-up, royalty-free, non-exclusive, irrevocable, perpetual, worldwide license, with the right to sublicense to Spark Affiliates (and without any right to sublicense to any Third Party), under Pfizer Background Manufacturing Technology and Pfizer Manufacturing Process Improvement Technology and under Pfizer’s interest in Joint Manufacturing Process Improvement Technology to Manufacture Compounds and Licensed Products in order to perform its obligations under Phase I/II Clinical Trials and the Manufacturing Technology Transfer Plan.

		
	(e) 
	Subject to the terms of this Agreement (and for the avoidance of doubt without limiting Spark’s exclusivity obligations under Section 2.11), Pfizer hereby grants to Spark a fully paid-up, royalty-free, non-exclusive, irrevocable, perpetual, worldwide license, with the right to sublicense to Spark Affiliates and to Third Parties, under Pfizer Manufacturing Process Improvement Technology and under Pfizer’s interest in Joint Manufacturing Process Improvements to Manufacture compounds and products other than Compounds and Licensed Products.

		
	(f) 
	The Manufacturing Process Technology and the Spark Manufacturing Process Improvements constitute Confidential Information of Spark.  The Pfizer Background Manufacturing Technology, improvements and changes to the Pfizer Background Manufacturing Technology and Pfizer Manufacturing Process Improvement Technology constitute Confidential Information of Pfizer.  

Without limiting the generality of Section 6 (and subject to the terms and limitations in Section 6 except as set forth in the proviso at the end of this Section 5.8.2(f)), Pfizer shall not disclose (other than as consistent with its sublicense rights under the license grants set forth in Sections 5.8.2(a) and 5.8.2(b)) Manufacturing Process Technology or Spark Manufacturing Process Improvements, and shall not use (other than as permitted under the license grants set forth in Sections 5.8.2(a) and 5.8.2(b)) any (1) Manufacturing Process Technology or (2) Spark Manufacturing Process Improvements, in each case for the Manufacture [**] of any compound or product; provided that, for purposes of the restriction set forth in this sentence the exception in Section 6.6 shall not apply to such Confidential Information of Spark. 
		
	(g) 
	 The exclusions set forth in Section 2.5 shall apply to the licenses granted in this Section 5.8 as if such licenses were granted in Sections 2.1 and 2.2. 

		
	(h) 
	 Notwithstanding the foregoing, the license grants set forth above in subsections (a) and (d) shall not extend to factor IX gene therapy products other than Compounds and Licensed Products. 

		
	(i) 
	Neither Party shall file for patent protection for any Manufacturing Process Improvement made in the conduct of activities under this Agreement or in the practice of licenses granted hereunder without the other Party’s prior written consent, not to be unreasonably withheld, delayed or conditioned, and, except as to such Manufacturing Process Improvements as to which the Parties determine to file for patent protection, each Party will use the requisite efforts to ensure such Manufacturing Process Improvements are maintained as trade secrets.  Pfizer shall have the right to file for patent protection for any improvements or changes to Pfizer Background Manufacturing Technology which is not also Manufacturing Process Technology, and Spark shall not file for patent protection for any such improvements or changes to Pfizer Background Manufacturing Technology without Pfizer’s prior written consent.

		
	(j) 
	 The licenses granted in Sections 5.8.2(b), 5.8.2(c), 5.8.2(d) and 5.8.2(e), and the restrictions set forth in Sections 5.8.2(f) and 5.8(h) shall survive any expiration or termination of this Agreement.” 

[Signature page follows]

In witness whereof, authorized representatives of the Parties have duly executed this Amendment as of the First Amendment Effective Date.
	
			
	PFIZER INC
	 
	SPARK THERAPEUTICS, INC.

	By: /s/ Robert J. Smith
	 
	By: /s/ Jeffrey D. Marrazzo

	Name:  Robert J. Smith
	 
	Name:  Jeffrey D. Marrazzo

	Title: Senior Vice President
	 
	Title: Chief Executive Officer

Appendix A
Technology Transfer Goals

Spark to provide Pfizer with materials and tech transfer documents in order for Pfizer and Spark to:
[**]

The Parties shall agree on the allocation of responsibility for the tasks needed to complete the above items within [**] days of the First Amendment Effective Date and shall add such allocation of responsibilities to this Appendix A when agreed.

Appendix B
Manufacturing Process Technology

[**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]